STOCKHOLM, April 1, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing ...
On April 15, two years after Eisai requested a marketing license for lecanemab in Europe, the European Commission has greenlit its use. The biologic’s long path included an initial rejection from the ...
Hosted on MSN
What is lecanemab, the newly approved Alzheimer's drug? Can it really slow down dementia?
Subscribe to our newsletter for the latest sci-tech news updates. Last week, Australia's Therapeutic Goods Administration (TGA) approved a new drug for early Alzheimer's diseases: lecanemab, sold ...
Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on the ...
Lecanemab's maintenance dosing regimen is now approved for early-stage Alzheimer's, transitioning from biweekly to once every four weeks after 18 months. Phase 2 and 3 trials confirmed lecanemab's ...
TOKYO and CAMBRIDGE, Mass., Sept 8, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has ...
The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...
There are many different causes of dementia, but Alzheimer's disease accounts for about 60%–80% of all cases. Last week, Australia's Therapeutic Goods Administration (TGA) approved a new drug for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results